{"id":1713,"date":"2025-04-09T12:00:24","date_gmt":"2025-04-09T04:00:24","guid":{"rendered":"https:\/\/www.hanchorbio.com\/?post_type=news&p=1713"},"modified":"2025-11-10T16:43:28","modified_gmt":"2025-11-10T08:43:28","slug":"hanchorbio-recognized-imapac-2025-taiwan-biopharma-excellence-award-strengthening-global-growth-strategy","status":"publish","type":"news","link":"https:\/\/www.hanchorbio.com\/en\/news\/hanchorbio-recognized-imapac-2025-taiwan-biopharma-excellence-award-strengthening-global-growth-strategy\/","title":{"rendered":"HanchorBio Recognized IMAPAC 2025 Taiwan Biopharma Excellence Award, Strengthening Global Growth Strategy"},"content":{"rendered":"
\n
HanchorBio Inc., a global biotechnology company dedicated to developing innovative immuno-medicines to address significant unmet medical needs in oncology and autoimmune diseases, has been awarded the 2025 Taiwan Biopharma Excellence Award at Biologics World Taiwan, hosted by IMAPAC. The company was also named \u201cCompany to Watch Out for in Taiwan\u201d, recognizing its innovation, leadership, and growth potential in biologics development.<\/span><\/div>\n
This industry recognition highlights HanchorBio\u2019s significant progress in advancing its proprietary Fc-Based Designer Biologics (FBDB\u2122) platform and underlines the company\u2019s potential as it prepares for its next phase of corporate growth, including an anticipated IPO in Taiwan.\u00a0<\/span><\/div>\n
\u00a0<\/span><\/div>\n
HanchorBio\u2019s CEO, Dr. Scott Liu, and Senior Director of CMC (Chemistry, Manufacturing, and Controls), Dr. Vivian Kuo, were invited to the IMAPAC awards ceremony to receive this honor.<\/span><\/div>\n
\u00a0\u00a0<\/span><\/div>\n
\u201cThis award is a testament to our team\u2019s dedication to building a globally competitive biotech company in Taiwan,\u201d said Scott Liu, Ph.D., Founder, Chairman, and CEO of HanchorBio. \u201cWe remain focused on expanding clinical development and providing better treatment options for patients worldwide while fostering talent and contributing to Taiwan\u2019s biotech industry.\u201d<\/span><\/div>\n
Driving Innovation in Immunotherapy<\/span><\/div>\n
HanchorBio\u2019s proprietary FBDB\u2122 platform leverages the antibody Fc region as a structural backbone to engineer next-generation multifunctional biologics with enhanced tumor specificity, improved safety, and durable efficacy. The platform integrates multi-target mechanisms to orchestrate both innate and adaptive immune responses, aiming to overcome the limitations of existing PD-1\/PD-L1 checkpoint immunotherapies.<\/span><\/div>\n
The company has successfully achieved proof-of-concept (PoC) for the FBDB\u2122 platform in multiple tumor models, supported by strong progress in molecular design, manufacturing processes, and CMC (Chemistry, Manufacturing, and Controls) development.<\/span><\/div>\n
\u00a0<\/span><\/div>\n
Taiwan\u2019s Emerging Global Biopharma Hub<\/span><\/div>\n
The IMAPAC\u2019s Taiwan Biopharma Excellence Awards recognize companies and teams driving innovation and operational excellence in biologics, cell therapies, and vaccine development. HachorBio\u2019s award reflects its commitment to accelerating biopharma innovation and contributing to Taiwan\u2019s growing influence in the global biotechnology ecosystem.<\/span><\/div>\n
HanchorBio\u2019s innovation in biologics R&D and high-quality manufacturing has earned industry-wide recognition for accelerating production timelines, reducing costs, and improving quality.<\/span><\/div>\n
\u00a0<\/span><\/div>\n
Advancing Clinical Development & Global Market Reach<\/span><\/div>\n
HanchorBio\u2019s lead candidate, HCB101, is currently being evaluated in multiple clinical trials across solid tumors and hematologic cancers:<\/span><\/div>\n
\u00a0\u2022 Phase 1a: Advanced solid tumors or relapsed\/refractory non-Hodgkin lymphomas (NCT05892718)<\/span><\/div>\n
\u00a0\u2022 Phase 1b\/2a: Evaluating efficacy and safety in advanced solid tumors<\/span><\/div>\n
\u00a0\u2022 Combination trials: HCB101 with cetuximab or bevacizumab + chemotherapy (FOLFOX or FOLFIRI) in RAS\/BRAF wild-type metastatic colorectal cancer (NCT06771522)<\/span><\/div>\n
HCB101 is a potential best-in-class Fc-fusion SIRP\u03b1 variant designed to enhance immune activation with reduced hematologic toxicity. Compared to conventional CD47 monoclonal antibodies, HCB101 exhibits higher tumor-specific binding and significantly lower risk of anemia and thrombocytopenia, addressing a key limitation of existing macrophage checkpoint inhibitors.<\/span><\/div>\n
\u00a0<\/span><\/div>\n
Committed to Global Biotech Leadership<\/span><\/div>\n
Winning the Taiwan Biopharma Excellence Award validates HanchorBio\u2019s accomplishments and underscores its immense future potential. The recognition from IMPAC further validates HanchorBio\u2019s innovative technology platform and its long-term strategy to become a leading global biotech company.<\/span><\/div>\n
Dr. Scott Liu added, \u201cWe are committed to contributing to Taiwan\u2019s biotech industry by building a globally competitive company. We aim to create an environment that attracts talent and provides more opportunities for young professionals in Taiwan.\u201d<\/span><\/div>\n
As global demand for cancer immunotherapies continues to rise, HanchorBio remains committed to advancing its pipeline and pursuing global partnerships to deliver accessible, next-generation immunotherapies for patients worldwide.<\/span><\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

HanchorBio Inc., a global biotechnology company dedicated to developing innovative immuno-medicines to address significant unmet medical needs in oncology and autoimmune diseases, has been awarded the 2025 Taiwan Biopharma Excellence Award at Biologics World Taiwan, hosted by IMAPAC. The company was also named \u201cCompany to Watch Out for in Taiwan\u201d, recognizing its innovation, leadership, and […]<\/p>\n","protected":false},"featured_media":962,"template":"","news-category":[],"class_list":["post-1713","news","type-news","status-publish","has-post-thumbnail","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/news\/1713","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/types\/news"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/media\/962"}],"wp:attachment":[{"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/media?parent=1713"}],"wp:term":[{"taxonomy":"news-category","embeddable":true,"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/news-category?post=1713"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}